Zero Reported DebtZero reported debt materially lowers financing risk for an early‑stage biotech. With no scheduled interest payments, the company has greater optionality to time equity or partnership financings, negotiate license deals, and avoid near‑term insolvency pressure while advancing preclinical programs.

Out‑licensing, Partner-driven Revenue ModelA business model focused on discovering assets and out‑licensing shifts later‑stage capital and commercialization risk to partners. Structurally, this asset‑light approach allows Sprint to monetize programs through upfronts, milestones and royalties without building a costly commercial infrastructure.

Lean Operating StructureA small, specialized headcount indicates low fixed overhead versus full‑scale biopharma. This lean setup helps preserve runway between financings, lets management concentrate resources on high‑value discovery projects, and supports flexible scaling when partner deals materialize.

Bears Say

Declining Revenue TrendA ~16% TTM revenue decline signals weakening partner income or fewer licensing milestones. Sustained top‑line contraction undermines internal funding capacity, reduces negotiating leverage with potential partners, and may reflect pipeline or commercialization attractiveness issues that harm long‑term viability.

Material Cash BurnSignificant negative operating and free cash flow means the business is not self‑funding and will require external capital to progress programs. This persistent burn increases dilution or refinancing risk, constrains the ability to advance multiple assets, and forces prioritization away from broader pipeline development.

Deep Losses And Equity ErosionLarge accumulated losses and a sharply reduced equity base reflect value erosion and weaken the balance sheet. This limits financial flexibility, heightens dependence on dilutive raises or partner funding, and reduces the company's ability to absorb development setbacks without impairing shareholder value.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was kr0.36 and its highest was kr2.35 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is kr228.97M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 84 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported kr1.073 earnings per share for the quarter, beating the consensus estimate of N/A by kr1.073.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of kr1.073 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in SE:SPRINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.